EGFR and cancer: Dysregulation of Notch signaling alone may not be sufficient to induce tumorigenesis, but it can promote the generation of pathologically specific cancer types by cooperating with oncogenic drivers, such as KRAS- and EGFR-activating mutations in lung adenocarcinomas or PTEN- and RB-inactivating mutations in small-cell lung cancer (Sriuranpong et al., 2001).